Previously doing business as Parasol Therapeutics, Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. The firm's proprietary technology platform - Hierotope - enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, the firm personnel are developing a robust pipeline of novel therapies for patients with unmet needs. Visterra has exclusive rights to Massachusetts Institute of Technology's intellectual property related to a family of early-stage monoclonal antibodies aimed at dengue virus. Visterra's most advanced program is in Phase 2 clinical development. Visterra was acquired by Otsuka Pharmaceutical in September 2018. The firm will continue to operate its business and develop its pipeline as a member of the Otsuka family of companies, retaining its talent and its location in Waltham, Massachusetts.
